February & end of 90 day exclusivity. We're just a handful of trading days away from the end of PFE's right of first refusal on Bracelet & mBC. The corporate presentation was missing for days just for minor language changes, perhaps to weigh the presentation more towards commercial development, FDA approvals and attracting a larger investor base. I'm of the opinion that the cleanup is in preparation for final negotiations, to cover all angles, as we wait for word on a PFE offer, which I'm sure is coming in short order. A poster on Stocktwits suggested selling/licensing Pela/ mBC to PFE for $5b, and doing the same for Roche and Pela/pancreatic. Not likely, but compelling.